TL;DR: Many large companies finance higher-certainty innovation internally, explore intermediate uncertainty through labs and ecosystem partnerships, and let founders and investors finance the least-certain search.
When a start-up reaches Business Model Fit and demonstrates traction, it may become an acquisition candidate. But this does not remove uncertainty. It replaces uncertainty about the venture with uncertainty about whether its value will survive new ownership—and whether the buyer can create enough additional value to justify the premium.
The more a deal depends on synergies to work, the less those synergies should be treated as upside. They become the acquisition’s burden of proof.
When a start-up reaches Business Model Fit and demonstrates traction, it may become an acquisition candidate. For a large company, this can look like an attractive way to reduce innovation risk. Instead of financing years of uncertain discovery, it can acquire a product, paying customers, specialist talent, and a business model that has already demonstrated that it can create, deliver, and capture value.
That can be entirely rational. But it is easy to draw the wrong conclusion from the evidence the start-up has created.
Traction tells us that the business model worked under a particular set of conditions: the start-up’s ownership, incentives, team, decision speed, customer relationships, partner network, architecture, and cost structure. An acquisition changes many of those conditions. At the same time, the acquisition price may require the buyer to create considerably more value than the start-up has demonstrated on its own.
The uncertainty has therefore not disappeared. It has changed its object.
Before acquisition, the question was whether the venture could work. After acquisition, the questions become whether its value will survive new ownership, whether the buyer can create additional value, and whether that additional value is sufficient to justify the price paid.
This distinction becomes particularly important when the acquisition case depends heavily on synergies. The more value the buyer must create after closing for the investment case to work, the less reasonable it is to describe those synergies as upside.
They have become part of the acquisition’s burden of proof.
Business Model Fit Does Not Prove Acquisition Fit
Recent OECD research illustrates why corporations may rationally enter after external ventures have already created evidence. A 2026 study covering 240 corporate investors and more than 44,000 start-ups found that corporate venture investors disproportionately targeted technology-intensive ventures with large patent portfolios. Those ventures were also more likely to be acquired later, although not necessarily by the original corporate investor.[1]
There is a sensible logic behind this division of labor. Founders and investors finance much of the uncertain search for a relevant problem, a workable solution, and a viable business model. A corporation can commit later, after evidence has accumulated.
The problem begins when evidence about the venture is allowed to migrate into claims about the acquisition.
I find it useful to separate three investment theses.
The venture thesis asks whether the target has found a viable business model. The transferability thesis asks whether the value demonstrated by the target will survive the change of ownership. The synergy thesis asks whether this particular buyer can create additional value beyond what the target could achieve independently.
These theses are related, but evidence for one does not automatically prove the others.
A start-up may have excellent retention, strong unit economics, proprietary technology, loyal customers, and rapid growth. All of that strengthens the venture thesis. It does not tell us whether customers will behave the same way after the change of ownership, whether key employees will remain, whether partners will continue contributing, or whether the target will retain its learning speed inside a larger organization’s governance.
Nor does it prove that the buyer’s sales channel can sell the offer, that its technology organization can integrate it without damaging the product, or that the combined organization can create enough additional value to earn back the acquisition premium.
An acquisition case can therefore contain excellent evidence for the venture thesis while relying largely on assumptions for transferability and synergy.
That is the first place where proven traction can create false confidence.
The Price Creates a Second Investment Case
The target initially attracts the buyer because of what it has already demonstrated. Then the valuation arrives.
At some price, the target’s standalone economics may no longer clear the buyer’s investment hurdle. The premium needs to be defended, and the acquisition case begins to move from demonstrated value toward combined potential: cross-selling, international expansion, shared technology, data access, procurement savings, overhead reduction, or faster market entry.
None of these claims is inherently unreasonable. The problem is how they are treated.
If the target’s standalone value already supports the investment and synergies create additional returns, they genuinely are upside. But if the acquisition fails to meet the buyer’s required return unless those synergies materialize, they are no longer optional benefits. The board is now financing a second investment case: the buyer’s ability to create value after closing.
Research published in Management Science makes this burden measurable. Ellahie, Hshieh, and Zhang calculate the minimum improvement in a target’s return on equity that an acquirer would need to achieve to break even on the acquisition price. They call it implied return-on-equity improvement.[2]
Deals requiring greater improvement proved less attainable and predicted worse subsequent acquirer performance. Over the first three years, acquirer ROE growth was 11 percentage points lower for high-burden deals than for low-burden deals. High-burden deals were also associated with higher operating costs, tighter financial constraints, lower investment, and larger and more frequent goodwill impairments.
This does not mean that paying a high price makes an acquisition wrong. It means something more useful: the price determines how much improvement the buyer must subsequently produce.
Valuation and integration are therefore not independent parts of the transaction. The valuation defines the performance burden. The integration thesis explains how the buyer intends to carry it.
Synergy Dependence Matters More Than Synergy Size
Consider two acquisitions that each claim €100 million in synergies.
In the first, the standalone value of the target already supports most of the investment case. Even if only €20 million of the projected synergies materializes, the acquisition can still generate an acceptable return.
In the second, €80 million must materialize simply to justify the purchase price and integration cost.
Both presentations may contain exactly the same €100 million synergy number, but they describe very different decisions. The first acquisition can tolerate substantial estimation and execution error. The second cannot.
This is why I think synergy dependence matters more than synergy size.
When standalone economics support the deal, synergies can reasonably be treated as contingent upside. When the deal fails without them, they become load-bearing assumptions.
A recent NBER paper provides an interesting parallel. It shows that among proposed mergers, different sources of expected profitability can compensate for weakness elsewhere because the transaction must clear an overall profitability threshold.[3] The paper examines merger efficiencies and market power rather than corporate board decision-making, so it does not demonstrate that a particular synergy estimate has been exaggerated.
But it suggests an important governance implication. The part of an investment case doing the most work because another part is weak should not receive less scrutiny simply because the overall case appears attractive.
It should receive more.
The claim required to rescue the deal deserves the highest evidence standard.
The reason is simple: necessity raises the cost of being wrong.
More Detail Is Not More Evidence
Once a deal depends on synergies, there is a natural tendency to make those synergies increasingly concrete. The mechanism becomes more detailed. The spreadsheet gains more lines. Forecasts acquire precise dates, conversion rates, retention assumptions, integration milestones, and responsible executives.
That detail can be valuable because it makes assumptions inspectable. But it can also create an illusion of evidence. A forecast does not become better supported merely because an uncertain assumption has been expressed to two decimal places.
A 2026 working paper examining synergy guidance in 12,176 US acquisitions found that investors responded positively when buyers discussed synergies and more strongly when estimates were more intensive or numerically larger.[4] Longer-term results were less favorable. Synergy disclosers experienced weaker post-merger operating performance and more frequent and larger goodwill impairments. Larger numerical estimates also predicted downward revisions and lower long-run stock returns.
The paper has not completed peer review, so its estimates should not be treated as settled. But the distinction it raises is valuable.
A synergy statement can improve the acquisition story before it improves the business.
The deal team needs to make the acquisition understandable and approvable. The board has a different job: determining whether the material presented is not only coherent, but predictive.
The Buyer Must Become Part of the Diligence
This leads to an asymmetry in many acquisition processes that deserves more attention. Diligence examines the unfamiliar target in extraordinary detail while treating the buyer as if its capabilities were already known.
Once the acquisition depends materially on synergies, that assumption no longer holds. The buyer itself becomes part of the hypothesis.
Take cross-selling. A large installed customer base is often presented as evidence for a revenue synergy. But the customer base is not the synergy. It is a resource. The synergy exists only if relevant customers actually buy the acquired offer through the buyer’s channel at an acceptable acquisition and delivery cost.
The same applies to the sales organization. Having thousands of salespeople does not demonstrate that they can sell an unfamiliar product. They may lack specialist knowledge, appropriate incentives, the right customer relationships, implementation support, or simply the management attention required to prioritize another offer.
Technology, procurement, data, brand, and international presence should be treated in the same way.
Resources are inputs. Synergies are realized outcomes.
That creates an important distinction between inventory and capability evidence.
“We have the channel” tells us what the buyer possesses.
“We have repeatedly sold this type of offer through this channel to comparable customers under comparable conditions” tells us something about what the buyer can do.
If the buyer has never performed the intervention required by the acquisition case, then there is another venture hidden inside the acquisition: building the buyer capability required to justify the price.
That uncertainty belongs in both the valuation and the decision.
Ownership Can Damage the Evidence You Are Buying
There is another complication. The value of a start-up rarely resides only in its product, contracts, patents, and employees. It may also depend on less visible conditions: direct access to customers, rapid product decisions, trusted ecosystem relationships, a focused roadmap, founder and employee incentives, partner neutrality, or freedom from the buyer’s architecture, procurement, compliance, and reporting processes.
An acquisition does not simply transfer those conditions from one owner to another.
It changes them.
OECD research covering start-ups in 60 countries between 2001 and 2021 found that patenting declined after acquisition without a corresponding increase in the acquirer’s innovation activity.[5] Patents are an incomplete measure of innovation, and this does not establish that every acquisition suppresses useful output. It does show why purchasing an innovative company cannot be equated with preserving its innovation trajectory.
Research on acquisitions of firms involved in open-source projects provides another view of the mechanism. Collaboration intensified when acquirers sought to protect the target’s complementarities and continued investing in partner relationships. It declined when acquisitions were primarily oriented toward extracting technology or employees. Structural independence also supported collaboration in protection-oriented acquisitions.[6]
Customers, employees, and partners are not passive assets. Their behavior can change when ownership changes.
That means every material synergy claim should have a corresponding shadow question. If the acquisition asks what the buyer can add, it should also ask what ownership might remove.
The answer may not appear as a line in the integration budget. Lost value may instead surface as slower learning, weaker partner contributions, employee departures, customer churn, reduced differentiation, or a delayed roadmap.
Those are still acquisition costs.
Integration Must Follow the Value Mechanism
This becomes particularly important when an acquisition promises both cost and revenue synergies.
Cost synergies typically require some combination of standardization, consolidation, elimination, and control. Revenue synergies are more likely to depend on access, coordination, customer trust, local judgment, and continued differentiation.
The interventions are not necessarily compatible.
A study of 1,452 US acquisitions found that greater integration was associated with better performance in deals emphasizing cost synergies. For revenue-synergy deals, the relationship followed an inverted U: some integration improved performance, but additional integration eventually reduced it.[7]
A buyer can therefore make the cost case more visible while simultaneously weakening the conditions required for the revenue case. Standardizing technology may reduce operating expense while slowing the target’s roadmap. Consolidating sales may reduce duplication while weakening specialist customer relationships. Centralizing decisions may simplify governance while reducing the target’s learning speed.
This is why “How much should we integrate?” is the wrong question.
The more useful question is:
Which resources must be combined to create each source of value, and which conditions must remain protected for that value to exist?
Integration should follow the value mechanism rather than organizational preference.
Ownership Must Earn Its Irreversibility
There is one final assumption worth examining: that strategic value requires ownership.
Acquisition is only one way to obtain access to technology, customers, capabilities, data, talent, or markets. Licensing, distribution agreements, minority investments, joint ventures, earn-outs, staged ownership, and other structures can sometimes provide strategic access while allowing the buyer to purchase additional evidence before making a larger commitment.
None of these alternatives is automatically superior. In some situations, control genuinely is necessary.
But that is precisely what the acquisition case should demonstrate.
Which source of value actually requires ownership? Which could be obtained contractually? What uncertainty could be reduced before full commitment? What additional value justifies the acquisition premium, integration exposure, and loss of reversibility?
A seller may refuse an alternative structure. That can constrain the transaction. It does not demonstrate that full ownership creates value.
The relevant comparison is therefore not acquisition versus doing nothing.
It is acquisition versus the best credible alternative for obtaining the strategic value being sought.
What the Board Is Actually Deciding
Acquiring a start-up after Business Model Fit can be a rational part of an innovation strategy. It allows a corporation to commit after external actors have absorbed much of the uncertainty involved in discovering whether a viable business model exists.
But that evidence belongs primarily to the venture thesis.
The board still has to evaluate whether the value demonstrated by the venture will survive transfer and whether this particular buyer can create enough additional value to justify the price.
A decision-ready acquisition case therefore needs to distinguish the target’s demonstrated standalone value from the conditions that produced it, determine which of those conditions must survive new ownership, identify how much additional value the price requires, make the mechanism behind each material synergy explicit, and establish whether the buyer has actually demonstrated the capabilities required to execute those mechanisms.
It should also account for value the acquisition itself could destroy and compare ownership with less irreversible ways of obtaining the same strategic access.
A start-up with proven traction has already answered an important question:
Can this business model work?
An acquisition asks a different one:
Can it still work here, under us, at this price?
The higher the premium, the more value the buyer must create after closing. And the more the deal depends on that value, the less reasonable it is to call synergies upside.
They are load-bearing assumptions.
The assumptions carrying the commitment should carry the highest burden of proof.
Apply the Transferability and Synergy-Dependence Gate
The argument above identifies where uncertainty moves after a proven venture becomes an acquisition target. The practical problem is how to prevent that uncertainty from disappearing inside a valuation model, synergy spreadsheet, or integration plan.
The Transferability and Synergy-Dependence Gate is designed for the point before an investment committee or board approves an acquisition. It does not replace valuation, legal diligence, or integration planning. It connects them around a single decision:
Does the evidence justify paying today for value that must first survive transfer and then be increased by the buyer?
The result is a one-page Acquisition Burden Record that makes explicit what the buyer is committing to, which assumptions carry that commitment, and what evidence supports them.
